Oncology Central

Tumor heterogeneity-based resistance guides personalized cancer medicine

0

Recent evidence on tumor heterogeneity shapes a new era in achieving personalized cancer medicine. Indeed, despite advances in modern oncology with standardized single biopsy-based approaches, limitations still exist in predicting resistance to therapies and tumor progression.

To view restricted content, please:
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.